LACRISERT: payments to doctors
Payments that named LACRISERT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Bausch & Lomb, A Division Of Bausch Health US, LLC?
Bausch & Lomb, A Division Of Bausch Health US, LLC reported the most payments naming LACRISERT. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $34K
- Providers
- 17
- Transactions
- 17
- Average per transaction
- $2,005
The per-transaction average — $2,005 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 17 providers the average total is $2,005, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | $33,940 | 99.6% |
| Bausch & Lomb Americas Inc. | $86 | 0.3% |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | $57 | 0.2% |
Other products from Bausch & Lomb, A Division Of Bausch Health US, LLC
The company that reported the most payments naming LACRISERT also reports against these.
- ULTRA$4,538,516
- BIOTRUE$3,757,036
- VISUDYNE$3,277,416
- VYZULTA$2,819,288
- BIOTRUE ONE DAY$2,764,451
- OPHTHALMIC INSTRUMENTS$2,306,528
- INFUSE$1,799,456
- LOTEMAX SM$1,542,951
- ENVISTA$1,526,231
- TRULIGN TORIC$1,270,052